Aptevo Therapeutics Signs Equity Purchase Agreement

Aptevo Therapeutics ( (APVO) ) just unveiled an announcement.

On June 16, 2025, Aptevo Therapeutics entered into a Standby Equity Purchase Agreement with Yorkville, allowing the company to issue and sell up to $25 million of its common stock over the next 36 months. This agreement provides Aptevo with financial flexibility to support its operations, though it is subject to certain conditions and limitations, including stockholder approval for exceeding specific share issuance thresholds.

The most recent analyst rating on (APVO) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.

Spark’s Take on APVO Stock

According to Spark, TipRanks’ AI Analyst, APVO is a Underperform.

Aptevo Therapeutics’ stock score is significantly impacted by its challenging financial performance, marked by declining revenues, high leverage, and negative cash flows. The technical analysis indicates bearish momentum, while the valuation is weakened by persistent losses. However, promising developments in its oncology pipeline offer potential upside if successfully executed.

To see Spark’s full report on APVO stock, click here.

More about Aptevo Therapeutics

Aptevo Therapeutics Inc. operates in the biotechnology industry, focusing on the development of novel immunotherapy treatments for cancer and other life-threatening diseases. The company specializes in leveraging its proprietary ADAPTIR platform to create therapeutic candidates aimed at improving patient outcomes.

Average Trading Volume: 279,746

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.56M

See more insights into APVO stock on TipRanks’ Stock Analysis page.